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ABSTRACT: Gold nanoparticles have shown great prospective in cancer diagnosis and therapy, but 
they can not be metabolized and prefer to accumulate in liver and spleen due to their large size. The 
gold nanoclusters with small size can penetrate kidney tissue and have promise to decrease in vivo 
toxicity by renal clearance. In this work, we explore the in vivo renal clearance, biodistribution, and 
toxicity responses of the BSA- and GSH-protected gold nanoclusters for 24 hours and 28 days. The 
BSA-protected gold nanoclusters have low-efficient renal clearance and only 1% of gold can be cleared, 
but the GSH-protected gold nanoclusters have high-efficient renal clearance and 36 % of gold can be 
cleared after 24 hours. The biodistribution further reveals that 94% of gold can be metabolized for the 
GSH-protected nanoclusters, but only less than 5% of gold can be metabolized for the BSA-protected 
nanoclusters after 28 days. Both of the GSH- and BSA-protected gold nanoclusters cause acute 
infection, inflammation, and kidney function damage after 24 hours, but these toxicity responses for the 
GSH-protected gold nanoclusters can be eliminated after 28 days. Immune system can also be affected 
by the two kinds of gold nanoclusters, but the immune response for the GSH-protected gold 
nanoclusters can also be recovered after 28 days. These findings show that the GSH-protected gold 
nanoclusters have small size and can be metabolized by renal clearance and thus the toxicity can be 
significantly decreased. The BSA- protected gold nanoclusters, however, can form large compounds and 
further accumulate in liver and spleen which can cause irreparable toxicity response. Therefore, the 
GSH-protected gold nanoclusters have great potential for in vivo imaging and therapy, and the BSA-
protected gold nanoclusters can be used as the agent of liver cancer therapy.  
 
 
1. Introduction 
Gold-based nanomaterials have been focused 
owing to their distinct optical properties and 
potential applications in photothermal therapy, 
radiation therapy, and contrast agent [1, 2, 3, 4, 5]. 
Therefore, in vivo toxicity of gold nanoparticles 
(NPs) has received wide interest [6, 7]. It has 
been found that the in vivo toxicity of gold NPs is 
directly related to the size, shape and surface 
coating, exposure dose, and administration routes 
[7, 8, 9, 10, 11, 12, 13, 14]. However, it is widely 
conceived that gold NPs have high-level 
accumulation in the liver and spleen, and these 
accumulations can induce the gene changes and 
liver necrosis [15, 16]. Therefore, it is desirable 
to find the metabolizable gold NPs to decrease 
the in vivo toxicity.  
It has been demonstrated that the size plays a 
dominant role in metabolism of NPs. Small 
semiconductor NPs, namely quantum dots (QDs) 
can be cleared by renal filtration and urinary 
excretion [14]. It is suggested that QDs smaller 
than 5.5 nm can be rapidly and efficiently 
metabolized by renal clearance, and QDs larger 
than 15 nm can prevent the renal excretion and 
can be accumulated in the liver and spleen [16, 
17, 18]. Indeed, in another independent work, it 
has also been found that 4-6 nm ZnS and CdSe 
QDs can be cleared by kidney, and only small 
amounts QDs can be found in the spleen, kidney, 
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and bone marrow [14]. However, in the practical 
in vivo experiment, the metabolism of gold NPs is 
also closely related to surface chemistry. Naked 
gold NPs without coatings can cause serious 
aggregation and NPs can accumulate in liver. For 
example, all sizes of naked gold particles (5-100 
nm) can cause high organ accumulation, and the 
liver and spleen are dominant targeting organs 
[19, 20, 21, 22]. Even using the coating, 
physiological environment may also cause the 
degeneration of coating and induce the failure of 
designing. A case in point is that the polyethylene 
glycol (PEG) coating can decrease the zeta 
potential of gold NPs and further prevent the 
aggregation partially in the blood, but these 
coating still can not decrease the liver and spleen 
accumulation and improve the metabolism of 
gold NPs. It has been found 5 nm PEG-coated 
gold NPs have long time circulation in blood [15, 
23], and high accumulation in the liver [16, 21, 
24]. Thus, it is necessary to explore the renal 
clearance of smaller and more stable gold 
nanomaterials and decrease the side effects. 
Compared with traditional NPs, the size of 
gold nanoclusters (NCs) is smaller. Typical thiol-
protected Au25 NCs with the size of 1-2 nm will 
have stronger permeability and petention effect 
(EPR) than larger size particles. Besides, gold 
NCs have high luminescence efficiency and in 
vivo imaging can be achieved by fluorescence [25, 
26, 27, 28, 29, 30, 31, 32] instead of scattering of 
NPs [1] or two-photon luminescence of nanorod 
[33, 34, 35]. On the one hand, it is necessary to 
explore the renal clearance and metabolism of 
these clusters in order to decrease the 
accumulation of liver and spleen. On the other 
hand, it is desirable to illustrate the in vivo 
toxicity of Au25 luminescence NCs, which have 
important indications to both of the in vivo 
imaging and therapy. Herein, we perform the in 
vivo renal clearance and toxicity of the GSH- and 
BSA-protected Au25 NCs by evaluating the 
biodistribution, immune response, hematology, 
and biochemistry.  
2. Materials and methods 
2.1. Fabrication  
The BSA- and GSH-protected Au25 NCs were 
synthesized following the recent reported 
procedures [26, 36]. Briefly, for the BSA-
protected Au25 NCs, HAuCl4·3H2O solution (17 
mL, 5 mM, 37 °C) was added to the BSA 
solution (5 mL, 50 mg/mL, 37 °C), then, NaOH 
solution (0.5 mL, 1 M) was introduced, and the 
mixture was incubated at 37 °C for 12 h. The red 
photoluminescence of the BSA-protected Au25 
NCs was located at 650 nm. For the GSH-
protected Au25 NCs, reduced GSH (20 mM) was 
added into the HAuCl4·3H2O solution (8 mL, 5 
mM) and an aqueous solution of NaBH4, cooled 
at 0 °C, was injected rapidly into this mixture 
under vigorous stirring and ligand etching by 
adding GSH again. The photoluminescence was 
measured by using a Hitachi F4500 fluorescence 
spectrophotometer with a 100 W xenon lamp as 
the excitation source, and the excitation and 
emission wavelength are 480 nm and 650 nm, 
respectively. The size and morphology of the 
Au25 NCs were analyzed by using a Hitachi HF-
2000 field emission high-resolution TEM 
operating at 200 kV. 
2.2. Animal injections and sample collection 
Animals were purchased, maintained, and 
handled with protocols approved by the Institute 
of Radiation Medicine, Chinese Academy of 
Medical Sciences (IRM, CAMS). Female mice 
were obtained from IRM laboratories at 11 weeks 
of age and were housed 2 per cage in a 12 h/12 h 
light/dark cycle, and were given food and water 
ad libitum. Mice were randomly divided into 
three groups (six in each group): control group, 
the BSA- and GSH-protected Au25 NCs treated 
groups, respectively. 151 μg/ml BSA- and GSH-
protected Au25 NCs were used for the animal 
experiment using intraperitoneal injection, and 
concentration was up to 7550 μg/kg in the mice. 
Animals were injected with 100 μL of control, 
the BSA-, and GSH-protected Au25 NCs solution. 
At every day time points after injection, animals 
were weighed and assessed for behavioral 
changes. Using a standard saphenous vein blood 
collection technique, blood was drawn for 
hematology analysis (potassium EDTA collection 
tube). The analysis of standard hematological and 
biochemical examination was performed. For 
blood analysis, 200 μL of blood was collected 
from mice and separated by centrifugation into 
cellular and plasma fractions. Upon the 
completion of the last time point, mice were 
sacrificed by isoflurane anesthetic and angio 
catheter exsanguination. Major organs from those 
mice were harvested, fixed in 4% neutral 
buffered formalin, processed routinely into 
paraffin, stained with hematoxylin and eosin 
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(H&E) and pathology are examined by a digital 
microscope. 
2.3. Biodistribution and TEM observation  
The organs and original solutions of the BSA- 
and GSH-protected Au25 NCs treated mice were 
digested by using a microwave system CEM 
Mars 5 (CEM, Kamp Lintfort, Germany). The Au 
content was measured with an inductively 
coupled plasma mass spectrometer (ICP-MS, 
type Agilent 7500 CE, Agilent Technologies, 
Waldbronn, Germany). Blood cells were obtained 
after tail vein injection of 24 hours. For the TEM 
analysis, the solution was centrifuged and fixed 
with 2.5% glutaraldehyde in 0.03 M potassium 
phosphate buffer, pH 7.4. The cells were 
postfixed with 1% osmium tetroxide in 0.1 M 
sodium cacodylate buffer and 0.5% uranyl acetate 
in 0.05 M maleate buffer, which were then 
dehydrated in a graded series of ethanol and 
embedded in Epon. Ultrathin sections were cut 
and transferred on 200-mesh uncoated copper 
grids, stained with uranyl acetate, counter-stained 
with lead citrate. 
3. Results and discussions 
3.1. Synthesis and characterization of Au25 NCs 
 
 
Figure 1. (a) The TEM images and (b) size distribution of the GSH-protected Au25 NCs. (c) The TEM 
images and (d) size distribution of the BSA-protected Au25 NCs. (e) Optical absorption and (f) 
photoluminescence of the GSH- and BSA-protected Au25 NCs. It can be seen that the emission centre is 
located at 650 nm.  
 
The size distribution and photoluminescence of 
the GSH- and BSA-protected Au25 NCs are 
characterized by TEM and spectrophotometer in 
Fig.1. The average size of the monodisperse 
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GSH-protected Au25 NCs is 2.1 nm. The surface 
of the BSA-protected Au25 NCs has lots of BSA, 
which induces the increase of size up to 8.2 nm, 
similar to the recent reported results of 8.5 nm 
[31]. The large size of the BSA-protected Au25 
NCs is not difficult to understand, and the BSA 
contains lots of SH molecules which are easy to 
form large coating by Au-S interaction. The 
optical absorption of protected Au25 NCs has 
been performed in Fig.1 (e). For the BSA-
protected Au25 NCs, the 420 and 650 nm 
absorption bands have been observed, which are 
due to the optical absorptions of the BSA-
protected Au25 NCs. The optical absorption of the 
GSH-protected Au25 NCs presents 450 nm 
absorption band and the 650 nm band is too weak 
to observe. The optical absorption induces the 
luminescence of Au25 NCs, and the 
photoluminescences of the two NCs are presented 
in Fig.1 (f). The red emission at 650 nm 
represents the direct optical transition and the 
emergence of thiol protected Au25 NCs. Quantum 
efficiency of the BSA-protected Au25 NCs is 0.06 
while it is 0.001 for the GSH-protected Au25 NCs, 
which are related to the ligand molecule [37]. The 
metal doping or binding with hole-rich molecule 
can enhance the emission [38, 39, 40].  
3.2. Blood plasma stability 
When the Au25 NCs are injected, the NCs will 
firstly interact with blood plasma. To investigate 
human plasma stability and interaction with Au25 
NCs, Fig.2 (a) and (b) present the time-dependent 
optical absorption of the GSH- and BSA-
protected Au25 NCs in human blood plasma. It is 
necessary to point out that Au25 NCs have not 
presented any surface plasmon resonance (SPR) 
absorption in Fig.1 (e), which is the feature of 
large size gold NPs. However, after dilution of 
human plasma, the GSH- and BSA-protected 
Au25 NCs show the SPR absorption. The slight 
redshift of SPR has been observed in the two 
protected Au25 NCs. which indicate that the Au25 
NCs have slightly aggregated in solution, and 
NCs may transform into NPs gradually. The 
intensity of SPR is gradually decreased for the 
two kinds of protected NCs. The decreased SPR 
is related to the structure and optical properties of 
gold, which indicate the NCs have combined with 
the proteins in blood plasma and form the larger 
compounds. The BSA is macromolecule and it 
can cover the optical absorption of NCs. It is well 
known that the naked and citrate coated gold NPs 
have high zeta potential, and it prefers to 
aggregation in physiological environment. The 
BSA- and GSH-protected Au25 NCs have 
decreased the surface charge and activity, and it 
is helpful to improve the stability of NCs. To 
directly observe the NCs distribution in blood 
plasma, we performed the TEM observations.  
 
Figure 2. Stability of (a) GSH- and (b) BSA-
protected Au25 NCs in the human blood plasma 
has been tested using time-dependent optical 
absorption. (c) The TEM observations of the 
GSH- and BSA-protected Au25 NCs in blood cell 
of mice. 
As presented in Fig. 2 (c), the TEM images of 
the GSH- and BSA-protected Au25 NCs in blood 
give microscopic insight for the distribution of 
NCs. Fig.2 (c1-c3) and (c4-c6) present the image 
of the GSH-protected Au25 NCs and BSA-
protected Au25 NCs at different scales, 
respectively. For the GSH-protected Au25 NCs 
after 24 hours interaction, it has been found the 
partial NCs have aggregated slightly and the 
average size is in the range of 5-30 nm in Fig.2 
(c3). The NPs can be formed by several clusters, 
which can be widely observed. However, we also 
find lots of monodisperse NCs in Fig. 2(c2). We 
can conclude that some NCs have transformed to 
NPs, and the complex compounds including the 
biomolecule and gold can be found in the blood. 
However, the BSA-protected Au25 NCs can form 
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the large size NPs, and the average size is in the 
range of 40-80 nm. These results are in good 
agreement with the results of blood plasma 
stability in Fig.2 (a) and (b). These results are not 
surprising, and the PEG- and BSA-coated Au25 
NCs are easy to suffer aggregation in the solution 
physiological environment after long time 
exposure. These coating can reduce the zeta 
potential and surface activity, but blood protein 
includes lots of SH- and NH- group and can 
degenerate these coating. Therefore, gold can 
hybrid with some macromolecule proteins by Au-
S and Au-NH3 binding interaction which seem 
similar to surface coating [41, 42]. It can be 
found that the GSH-protected Au25 NCs have 
better stability than the BSA-protected Au25 NCs. 
Next, we will move to the renal clearance and 
metabolism of these NCs in in vivo experiment.  
3.3. In vivo biodistribution and renal clearance 
  Fig.3 (a) and (b) presents in vivo 
biodistribution of the GSH-and BSA-protected 
Au25 NCs after 24 hours and 28 days, because it 
is widely reported that gold NPs have long blood 
circulation time and bioaccumulation in the liver 
and spleen [15, 20, 43, 44, 45, 46, 47, 48]. For 24 
hours distribution, liver and spleen have high 
content. The GSH-protected Au25 NCs prefer to 
stay in spleen and the BSA-protected Au25 NCs 
have high concentration in liver. After 28 days, 
biodistribution of the two clusters are quite 
different. The BSA-protected Au25 NCs have 
very high concentrations in the liver (7295 ng/g) 
and spleen (6982 ng/g), but the GSH-protected 
Au25 NCs have low concentrations. Recalling 
biodistribution of gold particles of 10-100 nm [20, 
43], it can be found that Au concentration from 
the BSA-protected Au25 NCs in the liver and 
spleen is 2 times higher than the previous results, 
but the Au concentration from the GSH-protected 
Au25 NCs is 10 times lower than widely available 
results in liver [20, 43]. In addition, the BSA-
protected Au25 NCs can be found in the lung and 
kidney with Au concentration of 979 and 1206 
ng/g, respectively, but the GSH-protected Au25 
NCs have only 114 and 224 ng/g in lung and 
kidney, respectively. Only in heart, the BSA-
protected Au25 NCs have lower concentration 
than the GSH-protected Au25 NCs. The tiny Au 
content can be found in brain, which is not 
surprising because even 15 nm gold particles can 
also pass blood–brain barrier [43]. Both of the 
BSA and GSH- protected Au25 NCs have high 
concentration in reproductive system. The BSA-
protected Au25 NCs have extremely high 
bioaccumulation in liver and spleen, but the Au 
concentration for the GSH-protected Au25 NCs is 
sharply decreased. It is widely believed that the 
BSA-coated gold NPs are biocompatible 
materials in in vitro because BSA coating can 
modify surface chemistry and reduce toxicity [26, 
49], but the present experiment results clearly 
show that the in vivo toxicity is quite different 
from the in vitro toxicity, and the metabolism of 
the BSA-protected Au25 NCs is not good. 
However, the GSH- protected Au25 NCs are very 
interesting, which show self-clearance function 
and can be metabolized partially. 
To confirm these results and investigate the 
renal clearance, we also measure the Au 
concentration and content in urine. Fig.3 (c) 
shows the time-dependent Au concentration of 
the GSH and BSA-protected Au25 NCs in the 
urine. For the GSH-protected Au25 NCs, Au 
concentration is as high as 226 ng/g after 2 hours 
injection. With increasing time, the Au 
concentration gradually decreases to 38 ng/g. As 
a contrast, the Au concentration is only 1-4 ng/g 
for the BSA-protected Au25 NCs at these time 
range. Moreover, Fig.3 (d) shows the time-
dependent Au content of the GSH- and BSA-
protected Au25 NCs in the urine, which represents 
the metabolized Au amount by renal clearance. It 
can be seen that the total Au is 5568 ng for the 
GSH-protected Au25 NCs and 227 ng for the 
BSA-protected Au25 NCs after 24 hours 
metabolism, which indicate that 36 % of the 
GSH-protected Au25 NCs and only 1% of the 
BSA-protected Au25 NCs can be excreted by 
urine. After 28 days treatment, only 6% of Au 
can be found in the GSH-protected Au25 NCs 
treated mice, but more than 95% of Au can be 
found in the BSA-protected Au25 NCs treated 
mice. These results clearly show the GSH-
protected Au25 NCs can be metabolized by renal 
clearance. On the one hand, the average size of 
the GSH-protected Au25 NCs is as small as 2.1 
nm, and it can penetrate the kidney tissue to 
metabolize. On the other hand, the GSH-
protected Au25 NCs can slightly aggregate up to 
5-30 nm gradually in the blood plasma with 
increasing time, but the metabolism rate of NCs 
can reach the maximum after 2 hours injection. 
However, the average size of the BSA-protected 
Au25 NCs is about 8.2 nm. Furthermore, it can 
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form NPs larger than 40 nm in blood, which 
prevent metabolism. It has been proposed that the 
NPs larger than 15 nm can not be metabolized, 
and the 5 nm NPs can be cleared by renal 
excretion [14]. Similar findings have been 
reported in the small ZnS QDs, and it was found 
that the QDs coated with the organic molecule 
mercaptoundecanoic acid and BSA were cleared 
from plasma with a clearance of 0.59-1.23 mL 
min–1kg–1 [17]. Small clusters may be cleared and 
metabolized by kidney. 
 
 
Figure 3. Biodistribution of the GSH- and BSA-
protected Au25 NCs treated mice at (a) 24 hours 
and (b) 48 hours. (c) Time dependent Au 
concentration (clearance rate) and (d) Au content 
(total metabolism) in 24 hours. The BSA-
protected Au25 NCs have 10 times higher 
distribution in the liver and spleen than the GSH- 
protected Au25 NCs. Each point represents the 
mean ± standard deviation. Bars represent mean ± 
standard deviation.  
3.4. Body weight, immune response, and 
pathology 
Fig.4 (a) gives the body weight of mice treated 
by the two NCs. It can be seen that both of the 
BSA- and GSH- protected Au25 NCs at the dose 
of 7550 μg/kg don’t cause mortality compared to 
the control group within a 1-day observation 
period. During the study period, the treatment 
with Au25 NCs for 28 days doesn’t cause obvious 
adverse effects on growth, and no significant 
statistical differences are observed in body 
weight between the Au25 NCs-treated mice and 
control mice. Further, no abnormal clinical signs 
and behaviors are detected in both control and 
treated groups. Necropsy of the mice at the end of 
the experiment doesn’t show any macroscopic 
changes of the organs in these groups.  To further 
investigate the immune reaction of organ, we 
give the organ indexes of thymus and spleen for 
24 hours treated mice in Fig.4 (b) and for 28 days 
treated mice in Fig. 4 (c). To explicitly examine 
the grade of changes caused by malities, spleen 
and thymus indexes ( ) can be defined as: xS
)( animalalexperimentofWeight
)(organ alexperimentofWeight
S
g
mg
x 
 
For 24 hours treated mice, spleen index has no 
significant change. The thymus index, however, 
has significantly increased to 4.2 for the two 
kinds of protected Au25 NCs. For 28 days treated 
mice, the average values of spleen and thymus 
index in control group are 3.3 and 2.3, 
respectively. The spleen indexes of the mice 
treated by the GSH- and BSA-protected Au25 
NCs have no significant changes at the 
concentration of 7550 μg/kg. However, the 
thymus index of the BSA-protected Au25 NCs 
treated mice increases to 3.7, and there are 
significantly statistical differences between the 
treated groups and control group. The high dose 
of Au induces the acute immune responses after 
24 hours treatment, and these responses of the 
GSH-protected Au25 NCs are recovered after 28 
days, but that of the BSA-protected have not 
recovered. The BSA-protected Au25 NCs have 
induced more obvious immune response than that 
of the GSH-protected Au25 NCs. We next check 
the pathological results of organ pathology by 
using immunohistochemistry in Fig.5. It can be 
seen that the two NCs treated heart, spleen, and 
kidney have not caused appreciable pathological 
lesion. However, the local liver necrosis has been 
observed in the BSA-protected Au25 NCs, which 
indicate that liver suffers the unrecoverable 
damage. To quantify the toxicity of the two NCs, 
the next important step is assessment of standard 
hematology and biochemistry [50].  
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Figure 4. (a) Body weights of the GSH- and 
BSA-protected Au25 NCs treated mice. Spleen 
index and thymus index of mice after (b) 24 
hours and (c) 28 days treatments. Bars represent 
mean ± standard deviation. Data is analyzed by T 
student test, and star represents significant 
difference from the control group (p < 0.05). 
 
3.5. Hematology and biochemistry 
We select standard hematology markers for 
analysis, such as white blood cell (WBC), red 
blood cell (RBC), hematocrit (HCT), mean 
corpuscular volume (MCV), hemoglobin (HGB), 
platelet (PLT), mean corpuscular hemoglobin 
(MCH), and mean corpuscular hemoglobin 
concentration (MCHC). Hematology results for 
the GSH- and BSA-protected Au25 NCs are 
presented in Figure 6. For 24 hours treated mice, 
the WBC and RBC in mice treated with the BSA-
protected Au25 NCs increase significantly. 
Similarly, the MCH and MCHC from mice 
treated with the two NCs also increase 
significantly. After 28 days, the WBC and HGB 
still increase for the BSA-protected Au25 NCs 
treated mice. Other parameters, such as HCT, 
MCV, and PLT have no significant difference, 
which indicates tiny damage to the mice. 
However, all parameters have recovered for the 
GSH-protected Au25 NCs treated mice after 28 
days. The WBC is sensitive to the physiological 
response in mice. The rise of WBC in mice 
treated with the BSA- protected Au25 NCs 
indicates an inflammatory response. After 28 
days, the BSA-protected Au25 NCs still show 
toxicity.  
 
Figure 5. Pathological results from the heart, 
liver, spleen, and kidney of the GSH- and BSA-
protected Au25 NCs after 28 days. Appreciable 
pathological changes have not been found in all 
these organs expect for liver in the BSA-
protected Au25 NCs. 
 
Furthermore, we present the biochemistry 
results of the GSH- and BSA-protected Au25 NCs 
in Fig.7 including (a) Alanine transaminase 
(ALT), (b) Aspartate transaminase (AST), (c) 
total protein (TP), (d) albumin (ALB), (e) blood 
urea nitrogen (BUN), (f) creatinine (CREA), (g) 
globulin (GLOB), and (h) total bilirubin (TBIL). 
We emphasize the ALT, AST, and CREA, 
because they are closely related to the liver and 
kidney function of mice. After 24 hours treatment, 
it can be found that the CREA increases for the 
two kinds of Au25 NCs treated mice, and the AST 
and BUN increase for the GSH-protected Au25 
NCs treated mice. Besides, the GLOB also 
increases for the two kinds of NCs treated mice. 
Both of the GHS- and BSA-protected Au25 NCs 
have caused the acute damage for liver and 
kidney after 24 hours. After 28 days, the CREA 
for the BSA-protected Au25 treated mice 
decreases and indicates that kidney function can 
not be recovered. However, all parameters for the 
GSH-protected Au25 NCs treated mice have 
recovered. 
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Figure 6. Hematology results of the GSH- and 
BSA-protected Au25 NCs treated mice after 24 
hours and 28 days. These results show mean and 
standard deviation of white blood cells (a), red 
blood cells (b), hematocrit (c), mean corpuscular 
volume (d), hemoglobin (e), platelets (f), mean 
corpuscular hemoglobin (g), mean corpuscular 
hemoglobin concentration (h). Bars represent 
mean ± standard deviation. Data is analyzed by T 
student test, and star represents significant 
difference from the control group (p < 0.05). 
The ALT and AST are mainly distributed in 
liver cells, and their values rise with necrosis of 
liver cells. The levels of these enzymes 
correspond well with the extent of liver cell 
damage, and are commonly used as indicators of 
liver function. These two enzymes are distributed 
differently among the liver cells. The ALT 
mainly exists in the cytoplasm of liver cells, 
whereas the AST mainly exists in the cytoplasm 
and mitochondria of liver cells. Therefore, the 
increase of AST in our mice treated with the 
GSH-protected Au25 NCs indicates acute damage 
to liver cells after 24 hours. However, 
biodistribution shows that the concentration of 
the GSH-protected Au25 NCs in the liver is not as 
high as that reached by the BSA-protected Au25 
NCs, which indicates that the liver damage 
caused by the GSH-protected Au25 NCs may be 
due to metabolism of the NCs. However, it is still 
not clear whether Au can be metabolized by liver. 
In contrast, the BSA-protected Au25 NCs reach 
high concentration in the liver, but liver function 
is not significantly affected, showing that the 
BSA-protected Au25 NCs don’t cause direct 
damage to the liver. The CREA is another 
important indicator of kidney function. 
Endogenous human CREA is a product of muscle 
metabolism. In muscle, creatine mainly generates 
CREA slowly through nonenzymatic dehydration, 
which is then released into the blood, with 
excretion in the urine. The serum CREA 
concentration depends on the glomerular 
filtration rate. However, serum CREA is not 
entirely consistent with the CREA clearance rate, 
and the CREA clearance is more sensitive than 
serum CREA. In early renal dysfunction 
(decompensated), the CREA clearance rate and 
serum CREA are normal. When the glomerular 
filtration rate rises to above 50% of normal, 
serum CREA begins to rise rapidly. Therefore, 
when the serum CREA is significantly higher 
than normal, kidney function is serious damaged. 
The increase of CREA in mice treated with the 
two kinds of NCs is closely related to kidney 
function, although the kidney is not the main 
target organ for the GSH-protected Au25 NCs. 
However, lots of Au25 NCs can be found in urine 
and thus kidney participates in the metabolism of 
the GSH-protected Au25 NCs. After 28 days, the 
GSH-protected Au25 NCs don’t induce any 
kidney damage, but the BSA-protected Au25 NCs 
still cause some damage by decreasing total 
protein and globulin. It can be conceived that 
these toxicity responses of the BSA-protected 
Au25 NCs are from the Au accumulation in spleen 
and liver. The Au25 NCs firstly cause the acute 
immune response with decreasing thymus index. 
Subsequently, the continuous Au accumulation in 
liver and spleen destroys the immune system and 
causes the unrepairable damage. Further, the liver 
and kidney can not obtain the protectation by 
immune system. Finally, these damages can be 
reflected by the clinical hematology and 
biochemistry. 
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Figure 7. Blood biochemistry results of the 
GSH- and BSA-protected Au25 NCs treated mice 
after 24 hours and 28 days. These results show 
mean and standard deviation of ALT (a), AST (b), 
total protein (c), albumin (d), blood urea nitrogen 
(e), creatinine (f), globulin (g), total bilirubin (h). 
Bars represent mean ± standard deviation. These 
results show the liver and kidney suffer serious 
damage for the two NCs after 24 hours. The liver 
and kidney function for the GSH-protected Au25 
NCs can be recovered after 28 days. Bars 
represent mean ± standard deviation. Data is 
analyzed by T student test, and star represents 
significant difference from the control group (p < 
0.05). 
3.6. Outline of metabolism 
Synthetically, we summary these findings in 
Fig.8. The GSH-protected Au25 NCs have slight 
aggregation and small NCs can be metabolized 
by urine, and thus these NCs have little 
accumulation in the liver. The BSA-protected 
Au25 NCs, however, suffer significant 
aggregation in the blood and form large size NPs, 
and these NPs can be accumulated in liver and 
spleen without metabolism. Subsequently, the 
liver and kidney function are affected by injection 
of the BSA- and GSH-protected Au25 NCs and 24 
hours acute toxic response is observed at high 
concentration of 7550 μg/kg. However, the liver 
and kidney functions for GSH-protected Au25 
NCs can be recovered after 28 days treatment due 
to the clearance of Au. As a contrast, the toxicity 
of the BSA-protected Au25 NCs can not be 
recovered due to the high accumulation of Au. In 
these clearance processing, kidney participate the 
metabolism of Au, and thus cause kidney damage 
at the short time, which is similar to the in vivo 
toxicity experiment of ZnS QDs [17]. The 
difference of biodistribution between the BSA- 
and GSH-protected Au25 NCs treated mice shows 
that the surface chemistry of Au plays a very 
important role in biodistribution and toxicity. The 
extreme high Au content for the BSA-protected 
Au25 NCs in liver can be utilized in targeting 
therapy for liver cancer. Meanwhile, the GSH-
protected Au25 NCs are easy to metabolize and 
have low content and accumulation in liver and 
spleen, and thus it has great potential and wide 
prospective for the in vivo imaging and therapy if 
the luminescence can be further enhanced in 
future.  
4. Conclusions 
In vivo renal clearance and toxicity studies of 
the BSA- and GSH-protected Au25 NCs treated 
mice are carried out. Animal weight, hematology, 
biochemistry, and biodistributions are 
characterized at the concentration of 7550 μg/kg 
after 24hours and 28 days. Biodistribution shows 
that the BSA-protected Au25 NCs mainly be 
accumulated in the liver and spleen, and the 
GSH-protected Au25 NCs have low concentration 
in all organs. After 24 hours, 36 % of the GSH-
protected Au25 NCs can be excreted by urine and 
only 1% of the BSA-protected Au25 NCs can be 
excreted by urine. Further, 94% of Au in the 
GSH-protected Au25 NCs can be metabolized by 
renal clearance, and less than 5% of Au can be 
metabolized in the BSA-protected Au25 NCs after 
28 days.  For 24 hours toxicity, blood chemistry 
reveals that the WBC of the GSH- and BSA-
protected Au25 NCs treated mice has significantly 
increased. Further, biochemistry results show that 
the CREA of the GSH- and BSA-protected Au25 
NCs treated mice increase, and kidney function is 
affected. However, these toxicity responses of the 
GSH-protected Au25 NCs can be eliminated after 
28 days, but the BSA-protected Au25 NCs still 
cause liver, kidney damage and the infection of 
mice,. The present work clearly shows the GSH-
protected Au25 NCs are metabolizable by renal 
clearance and have not induced the considerable 
9
 
toxicity responses. These conclusions are very 
important for future cancer therapy, drug delivery, 
and bioimaging of Au25 NCs. 
  
 
Figure 8. Outline of the biodistribution and renal clearance the GSH- and BSA-protected Au25 NCs. 
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